Synthorx’s (NASDAQ:THOR) quiet period will end on Wednesday, January 16th. Synthorx had issued 11,912,727 shares in its IPO on December 7th. The total size of the offering was $131,039,997 based on an initial share price of $11.00. During the company’s quiet period, insiders and underwriters that worked on the IPO are prevented from issuing any research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the end of the company’s quiet period, it’s expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

A number of brokerages recently issued reports on THOR. HC Wainwright began coverage on shares of Synthorx in a research report on Wednesday, January 2nd. They set a “buy” rating and a $30.00 price target for the company. Jefferies Financial Group began coverage on shares of Synthorx in a research report on Wednesday, January 2nd. They set a “buy” rating and a $21.00 price target for the company.

Shares of NASDAQ THOR opened at $13.74 on Friday. Synthorx has a 1 year low of $11.00 and a 1 year high of $18.46.

In other news, Director Orbimed Advisors Llc bought 1,363,636 shares of the firm’s stock in a transaction on Tuesday, December 11th. The stock was acquired at an average cost of $11.00 per share, with a total value of $14,999,996.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Tighe Reardon bought 545,455 shares of the firm’s stock in a transaction on Tuesday, December 11th. The stock was purchased at an average cost of $11.00 per share, with a total value of $6,000,005.00. The disclosure for this purchase can be found here. Over the last three months, insiders have purchased 6,454,546 shares of company stock valued at $71,000,006. 1.70% of the stock is currently owned by corporate insiders.

COPYRIGHT VIOLATION WARNING: “Synthorx Inc’s Quiet Period Will End on January 16th (NASDAQ:THOR)” was posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright & trademark legislation. The correct version of this report can be read at https://theolympiareport.com/2019/01/13/synthorx-incs-quiet-period-will-end-on-january-16th-nasdaqthor.html.

About Synthorx

Synthorx, Inc, a biotechnology company, discovers and develops protein therapeutics. The company's lead product candidate is THOR-707, a variant of IL-2 that is in development in various tumor types as a single agent and in combination with an immune checkpoint inhibitor. The company was founded in 2014 and is headquartered in La Jolla, Calif.

Read More: What Factors Can Affect Return on Equity?

Receive News & Ratings for Synthorx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthorx and related companies with MarketBeat.com's FREE daily email newsletter.